抗血小板药物在经皮冠脉介入治疗中应用的新展

被引：2

作者：

陈明哲

张永珍

机构：

[1] 北京医科大学第三医院内科

来源：

引进国外医药技术与设备 | 1999年 / 07期

关键词：

抗血小板方案; 支架血栓形成; PTCA; 再狭窄; 心肌梗塞;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

1002 ; 100201 ;

摘要：

本文对抗血小板药物在经皮冠脉介入治疗中应用的最新成果作一综述和展望,重点讨论在介入性心脏病领域(PTCA、支架、再狭窄、围介入期心肌梗塞和急性心肌梗塞)内抗血小板方案应用的最新进展。

引用

页码：28 / 32

页数：5

共 12 条

[1]

Clinical risk factors for ischemic complications after percutaneous coronary interventions: Results from the EPIC trial[J] . Mark C. Thel,Robert M. Califf,James E. Tcheng,Kristina N. Sigmon,A.Michael Lincoff,Eric J. Topol,Stephen G. Ellis.American Heart Journal . 1999 (2)

[2] Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty [J].

Haase, KK ;

Mahrholdt, H ;

Schröder, S ;

Baumbach, A ;

Oberhoff, M ;

Herdeg, C ;

Karsch, KR .

AMERICAN HEART JOURNAL, 1999, 137 (02) :234-240

[3]

Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial[J] . A. Michael Lincoff,James E. Tcheng,Robert M. Califf,Dean J. Kereiakes,Thomas A. Kelly,Gerald C. Timmis,Neal S. Kleiman,Joan E. Booth,Craig Balog,Catherine F. Cabot,Keaven M. Anderson,Harlan F. Weisman,Eric J. Topol.Circulation . 1999 (15)

[4] Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction [J].

Neumann, FJ ;

Blasini, R ;

Schmitt, C ;

Alt, E ;

Dirschinger, J ;

Gawaz, M ;

Kastrati, A ;

Schömig, A .

CIRCULATION, 1998, 98 (24) :2695-2701

[5] Frontiers in interventional cardiology [J].

Topol, EJ ;

Serruys, PW .

CIRCULATION, 1998, 98 (17) :1802-1820

[6]

Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction[J] . Sorin J. Brener,Lawrence A. Barr,J.E.B. Burchenal,Stanley Katz,Barry S. George,Ancil A. Jones,Eric D. Cohen,Phillip C. Gainey,Harvey J. White,H. Barrett Cheek,Jeffrey W. Moses,David J. Moliterno,Mark B. Effron,Eric J. Topol.Circulation . 1998 (8)

[7] Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial [J].

Gibson, CM ;

Goel, M ;

Cohen, DJ ;

Piana, RN ;

Deckelbaum, LI ;

Harris, KE ;

King, SB .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (01) :28-34

[8] Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide [J].

Mandak, JS ;

Blankenship, JC ;

Gardner, LH ;

Berkowitz, SD ;

Aguirre, FV ;

Sigmon, KN ;

Timmis, GC ;

Gilchrist, IC ;

McIvor, M ;

Resar, J ;

Weiner, BH ;

George, BS ;

Talley, JD ;

Lincoff, AM ;

Tcheng, JE ;

Califf, RM ;

Topol, EJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (07) :1518-1524

[9]

Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy[J] . Sasan Ghaffari,Dean J. Kereiakes,A.Michael Lincoff,Thomas A. Kelly,Gerald C. Timmis,Neal S. Kleiman,James J. Ferguson,David P. Miller,Robert A. Califf,Eric J. Topol.The American Journal of Cardiology . 1998 (1)

[10] Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention [J].

Bhatt, DL ;

Lincoff, AM ;

Kereiakes, DJ ;

Tcheng, JE ;

Simoons, ML ;

van der Wieken, LR ;

Godfrey, N ;

Califf, RM ;

Topol, EJ .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (09) :1105-+

← 1 2 →